scispace - formally typeset
D

David L. King

Researcher at Pacific Northwest National Laboratory

Publications -  61
Citations -  6251

David L. King is an academic researcher from Pacific Northwest National Laboratory. The author has contributed to research in topics: Catalysis & Steam reforming. The author has an hindex of 35, co-authored 61 publications receiving 5500 citations. Previous affiliations of David L. King include University of South Florida.

Papers
More filters
Journal ArticleDOI

An overview of hydrogen production technologies

TL;DR: A review of technologies related to hydrogen production from both fossil and renewable biomass resources including reforming (steam, partial oxidation, autothermal, plasma, and aqueous phase) and pyrolysis is presented in this article.
Journal ArticleDOI

Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes.

TL;DR: The APP+PS1 transgenic mouse offers unique opportunities to develop therapeutics to treat or prevent Alzheimer's Disease through modulation of Abeta deposition/neuroinflammation.
Journal ArticleDOI

Progressive and gender-dependent cognitive impairment in the APPSW transgenic mouse model for Alzheimer’s disease

TL;DR: The presence of gender-related and progressive cognitive deficits in APP(SW) transgenic mice at a relatively early age is demonstrated, suggesting a pathophysiologic role for elevated levels of 'soluble' beta-amyloid in such impairments.
Journal ArticleDOI

Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months.

TL;DR: In this article, a comprehensive 6-week behavioral battery was used to characterize sensorimotor and cognitive performance of Tg2576 AD transgenic mice and nontransgenic (Tg-) controls aged 3, 9, 14, and 19 months.
Journal ArticleDOI

Correlation between cognitive deficits and Aβ deposits in transgenic APP+PS1 mice

TL;DR: It is argued that radial arm water maze testing of doubly transgenic mice may be a useful behavioral endpoint in evaluating the functional consequences of potential AD therapies, especially those designed to reduce Abeta load.